<DOC>
	<DOCNO>NCT00508261</DOCNO>
	<brief_summary>The purpose study demonstrate , 12-23 month old subject , non-inferiority meningococcal vaccine GSK134612 co-administered Infanrix hexa™ , compare vaccine administer individually licensed meningococcal vaccine Meningitec™ . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Co-Administration Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration Each Vaccine</brief_title>
	<detailed_description>Multicentre study 4 parallel group . One group receive GSK134612 co-administered Infanrix hexa™ , two group receive sequential administration GSK134612 Infanrix hexa™ final group receive Meningitec™ . For subject Groups B C , three blood sample take : prior first vaccination 1 month vaccination . For subject Groups A D , two blood sample take : prior 1 month vaccination .</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol . A male female , include , 12 23 month age time first vaccination . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Documented threedose primary vaccination DTPa , hepatitis B , inactivate polio Haemophilus influenzae type b conjugate vaccine , complete least 180 day administration first study vaccination . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration vaccine foreseen study protocol , include measles , mumps , rubella , varicella pneumococcal vaccine , within 30 day first dose vaccine ( ) 30 day last dose vaccine ( ) . Previous vaccination meningococcal polysaccharide vaccine serogroup A , C , W and/or Y . Previous vaccination meningococcal polysaccharide conjugate vaccine serogroup A , C , W and/or Y . Previous booster vaccination diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis Haemophilus influenzae type b . History meningococcal disease . Any confirm suspected immunosuppressive immunodeficient condition ( congenital secondary ) , include human immunodeficiency virus ( HIV ) infection , base medical history physical examination . History reaction allergic disease likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine plan administration study period . Additional criterion subject receive Infanrix hexa™ Hypersensitivity reaction due previous vaccination Infanrix hexa™ . Encephalopathy define acute , severe central nervous system disorder occur within 7 day follow vaccination generally consist major alteration consciousness , unresponsiveness , generalised focal seizure persist hour , failure recover within 24 hour .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Meningococcal vaccine</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Routine infancy vaccination</keyword>
	<keyword>Safety</keyword>
</DOC>